{"id":"rop-l-dopa","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Dyskinesia"},{"rate":null,"effect":"Hallucinations"},{"rate":null,"effect":"Orthostatic hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ropinirole directly stimulates dopamine receptors (particularly D2/D3), while L-Dopa is converted to dopamine in the brain to replenish depleted dopamine levels. Together, they provide complementary dopaminergic effects to reduce motor symptoms of Parkinson's disease. This combination approach allows for lower individual doses while maintaining therapeutic efficacy.","oneSentence":"ROP+L-Dopa is a combination therapy that pairs ropinirole (a dopamine agonist) with levodopa to enhance dopaminergic signaling in the brain for Parkinson's disease management.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:37:20.716Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"}]},"trialDetails":[{"nctId":"NCT00485069","phase":"PHASE4","title":"REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06","conditions":"Parkinson Disease, Parkinson's Disease","enrollment":123}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"ROP+L-Dopa","genericName":"ROP+L-Dopa","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ROP+L-Dopa is a combination therapy that pairs ropinirole (a dopamine agonist) with levodopa to enhance dopaminergic signaling in the brain for Parkinson's disease management. Used for Parkinson's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}